Buprenorphine use: The international experience
Buprenorphine use: The international experience
复制标题
DOI：
10.1086/508184
复制
发表时间：
2006-12-15
影响因子：
11.8
通讯作者：
Woody, George E.
中科院分区：
文献类型：
--
作者：
Carrieri, Maria Patrizia;Amass, Leslie;Woody, George E.
海洛因注射流行病和人体免疫机能丧失病毒（艾滋病毒）感染流行病的共同作用，使人们更加呼吁扩大对这两种疾病的有效治疗。丁丙诺啡和美沙酮现已被列入世界卫生组织的标准基本药物清单。在经验最丰富的法国，丁丙诺啡与因过量使用导致的死亡人数急剧减少有关，而丁丙诺啡转移似乎与剂量不足、社会脆弱性和来自多个提供者的处方有关。其他治疗模式（在美国、澳大利亚、德国和意大利）和丁丙诺啡在特定人群中的使用也在本文中进行了审查。在海洛因使用和艾滋病毒感染双重流行的国家，例如前苏联国家和其他东欧和亚洲国家，获得丁丙诺啡和美沙酮可能是减少艾滋病毒感染在注射吸毒者中传播和使他们更好地接受医疗保健的一个潜在工具。
The confluence of the heroin injection epidemic and the human immunodeficiency virus (HIV) infection epidemic has increased the call for expanded access to effective treatments for both conditions. Buprenorphine and methadone are now listed on the World Health Organization's Model Essential Drugs List. In France, which has the most extensive experience, buprenorphine has been associated with a dramatic decrease in deaths due to overdose, and buprenorphine diversion appears to be associated with inadequate dosage, social vulnerability, and prescriptions from multiple providers. Other treatment models (in the United States, Australia, Germany, and Italy) and buprenorphine use in specific populations are also reviewed in the present article. In countries experiencing a dual epidemic of heroin use and HIV infection, such as former states of the Soviet Union and other eastern European and Asian countries, access to buprenorphine and methadone may be one potential tool for reducing the spread of HIV infection among injection drug users and for better engaging them in medical care.